2018
DOI: 10.1016/j.vaccine.2018.02.050
|View full text |Cite
|
Sign up to set email alerts
|

A recombinant trivalent vaccine candidate against human adenovirus types 3, 7, and 55

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
18
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
6
1
1

Relationship

3
5

Authors

Journals

citations
Cited by 30 publications
(18 citation statements)
references
References 47 publications
0
18
0
Order By: Relevance
“…Because HAdV outbreaks are more prominent among trainees and low-rank soldiers recently discharged from training centers [20,21,34], such measures have been emphasized in training centers for new recruits [24]. Although an oral vaccine for HAdV-4 and -7 successfully controlled HAdV-ARI outbreaks in the United States military [35], it has not been adopted in the Korean military because HAdV-ARI is known to exhibit type-specific immunity, and HAdV-55 shares immunogenicity with HAdV-14 [9,36,37]. Several multi-valent HAdV vaccines targeting HAdV-55 are currently under development, but clinical application of these vaccines will take time [36,38].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Because HAdV outbreaks are more prominent among trainees and low-rank soldiers recently discharged from training centers [20,21,34], such measures have been emphasized in training centers for new recruits [24]. Although an oral vaccine for HAdV-4 and -7 successfully controlled HAdV-ARI outbreaks in the United States military [35], it has not been adopted in the Korean military because HAdV-ARI is known to exhibit type-specific immunity, and HAdV-55 shares immunogenicity with HAdV-14 [9,36,37]. Several multi-valent HAdV vaccines targeting HAdV-55 are currently under development, but clinical application of these vaccines will take time [36,38].…”
Section: Discussionmentioning
confidence: 99%
“…Although an oral vaccine for HAdV-4 and -7 successfully controlled HAdV-ARI outbreaks in the United States military [35], it has not been adopted in the Korean military because HAdV-ARI is known to exhibit type-specific immunity, and HAdV-55 shares immunogenicity with HAdV-14 [9,36,37]. Several multi-valent HAdV vaccines targeting HAdV-55 are currently under development, but clinical application of these vaccines will take time [36,38]. More resources should be focused on vaccine development, and HAdV molecular typing must be implemented in surveillance systems for proper selection of HAdV vaccines in the future.…”
Section: Discussionmentioning
confidence: 99%
“…Thus, HAdV‐B55 avoids herd immunity to HAdV‐B14, while retaining its respiratory pathogenicity . Recently isolated and genome‐characterized in China, HAdV‐B55 causes severe acute respiratory disease in immunocompetent adults worldwide , and of sufficient severity to warrant efforts to include it in a vaccine against other fatal respiratory adenoviruses, HAdV‐B3 and B7 . In contrast to marked hypervariability within HVRs of the HAdV‐D penton base gene and the entire fiber gene (see below), nucleotide diversity in the HAdV‐D hexon gene HVRs is comparatively less in HAdV‐Ds as compared to the other HAdV species .…”
Section: Human Adenovirus Species‐ and Type‐specific Features And Genmentioning
confidence: 99%
“…HAdV-5 was cultured in AD293 cells, purified and stored at −80°C. The 50% tissue culture infective dose of the virus was determined following the routine procedure, as previously described [17].…”
Section: Virusesmentioning
confidence: 99%